Bio Roundup: Nobel Prizes, Placebo Effect Rises, ICERs Fire & More
Summary
Congrats to this year’s Nobel Prize winners in medicine… although, we have to ask: For the US researchers who are honored, isn’t there something crushing about a call in the middle of the night from Sweden, interrupting a dream about the perfect protein-protein interaction? —The US Supreme Court denied an appeal by Acorda Therapeutics (NASDAQ: ACOR) to reinstate patents for its flagship multiple sclerosis drug dalfampridine (Ampyra), which expired last year. —Prometheus Biosciences, formerly known as Precision IBD, has signed a deal with Japan’s Takeda Pharmaceutical (NYSE: TAK) to find up to three potential therapies for inflammatory bowel disease and to develop companion diagnostics. —Alexion Pharmaceuticals (NYSE: ALXN) paid Stealth BioTherapeutics (NASDAQ: MITO) $30 million for an option to codevelop experimental drug elamipretide pending results from an ongoing Phase 3 study for a genetic mitochondrial disease. —In its first move since its recent management overhaul, Akcea Therapeutics (NASDAQ: AKCA) sold an experimental heart disease drug to Pfizer (NYSE: PFE) for $250 million upfront.
Classifications
AskAI Classifications
LabelsLinked Companies
